Search

Your search keyword '"Izutsu K"' showing total 283 results

Search Constraints

Start Over You searched for: Author "Izutsu K" Remove constraint Author: "Izutsu K" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
283 results on '"Izutsu K"'

Search Results

1. Plain language summary of the TRANSFORM study primary analysis results:liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

4. TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

6. PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT.

7. P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL

8. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

11. IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY.

12. OBINUTUZUMAB CAN BE ADMINISTERED AS A 90‐MINUTE SHORT‐DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: GAZELLE END OF INDUCTION ANALYSIS

13. FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

15. A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)

16. A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI‐8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T‐CELL LEUKEMIA‐LYMPHOMA (ATL)

17. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

18. Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial

19. Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel

20. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review

21. Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma

22. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

23. A platform trial with a registry study for rare cancers: MASTER KEY project

24. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

25. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

26. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

27. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS RELAPSING AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION: DATA FROM THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION

28. PB1890 VENETOCLAX ALONE OR IN COMBINATION WITH RITUXIMAB FOR JAPANESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

29. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

30. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL

31. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)

32. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO

33. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH AGGRESSIVE NATURAL KILLER CELL LEUKEMIA: A NATIONWIDE MULTICENTER ANALYSIS IN JAPAN

34. CLINICAL SIGNIFICANCE OF UPTAKE VALUE ON F18-FDG PET/CT AND HISTOLOGICAL GRADE IN 164 PATIENTS WITH FOLLICULAR LYMPHOMA INCLUDING TRANSFORMATION - A SINGLE CENTER RETROSPECTIVE STUDY

35. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

38. PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2.

39. Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology.

40. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

41. ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

42. Identification of cell-type-specific mutations in nodal T-cell lymphomas

49. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma

50. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma

Catalog

Books, media, physical & digital resources